Array's Rheumatoid Arthritis Drug Fails Study By: MarketMinute.com Stock News September 04, 2009 at 18:27 PM EDT A rheumatoid arthritis drug candidate developed by Array BioPharma Inc. (Nasdaq: ARRY) missed study goals. Analysts promptly downgraded the stock sending shares plummeting $0.88 to close at $2.90. Related Stocks: Array Technologies Inc